Literature DB >> 33691722

The V-BRCH Project: building clinical trial research capacity for HIV and noncommunicable diseases in Nigeria.

Muktar H Aliyu1,2,3, Mahmoud U Sani4, Donna J Ingles5, Fatimah I Tsiga-Ahmed6, Baba M Musa4,7, Carolyn M Audet5,8, C William Wester5,9,10.   

Abstract

Antiretroviral therapy has turned HIV into a chronic condition, with morbidity from HIV-associated noncommunicable diseases (NCDs) becoming more common as HIV-infected individuals live longer. In Nigeria, the additional challenge of an under-capacitated health system highlights the need for skilled clinical investigators who can generate evidence to tackle the double burden of HIV and NCDs. The Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (V-BRCH) programme is a training platform to create a cohort of skilled Nigerian investigators with the capacity to lead independent clinical trial research focused on the intersection of HIV and NCDs. V-BRCH will solidify an atmosphere of continuous mentoring and skills acquisition for physician faculty at the Aminu Kano Teaching Hospital via short- and medium-term learning opportunities, paired mentoring arrangements, and mentored research projects. Trainees will attend an annual faculty enrichment programme in Nashville, in addition to on-site workshops in Nigeria on HIV-associated NCD epidemiology, clinical trials methodology, evidence synthesis, qualitative research methods, stakeholder engagement, knowledge translation, and grant writing. Research-oriented junior faculty will undergo focused training in clinical trials administration and regulatory oversight. Scholars will share best practices through mentoring panels, regular 'Works in Progress' meetings, and monthly career development seminars. Competitive seed grants will be provided to mentor-mentee teams to promote targeted in-country pilot studies focused on HIV-associated NCDs. For long-term training, physician scientists will be supported to undergo enhanced Master of Public Health (MPH) training at Bayero University in Nigeria and Master of Science in Clinical Investigation (MSCI) training at Vanderbilt. Short-term regional courses, staff development workshops, and MPH curriculum refinement will help to strengthen institutional capacity in HIV-associated NCD clinical trial research. V-BRCH will create a cohort of skilled Nigerian scientists who will be able to compete for independent funding and design and implement high quality research that will generate evidence to inform policy and practice and lead to improved outcomes for Nigerians impacted by HIV-associated NCDs.

Entities:  

Keywords:  Clinical trials; HIV; Noncommunicable diseases; Research capacity; Training

Mesh:

Year:  2021        PMID: 33691722      PMCID: PMC7943703          DOI: 10.1186/s12961-020-00656-z

Source DB:  PubMed          Journal:  Health Res Policy Syst        ISSN: 1478-4505


  26 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Global confluence of infectious and non-communicable diseases -- the case of type 2 diabetes.

Authors:  M J Magee; K M Venkat Narayan
Journal:  Prev Med       Date:  2013-06-06       Impact factor: 4.018

Review 3.  HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low- and middle-income country settings.

Authors:  K M Venkat Narayan; Paolo G Miotti; Nalini P Anand; Lydia Mann Kline; Christine Harmston; Roman Gulakowski; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).

Authors:  Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun
Journal:  Am J Hematol       Date:  2018-02-02       Impact factor: 10.047

5.  High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda.

Authors:  Bazil Kavishe; Samuel Biraro; Kathy Baisley; Fiona Vanobberghen; Saidi Kapiga; Paula Munderi; Liam Smeeth; Robert Peck; Janneth Mghamba; Gerald Mutungi; Eric Ikoona; Jonathan Levin; Maria Assumpció Bou Monclús; David Katende; Edmund Kisanga; Richard Hayes; Heiner Grosskurth
Journal:  BMC Med       Date:  2015-05-29       Impact factor: 8.775

6.  Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy.

Authors:  Sanusi Muhammad; Mahmoud Umar Sani; Basil N Okeahialam
Journal:  Niger Med J       Date:  2013-05

7.  Identifying and Prioritizing Implementation Barriers, Gaps, and Strategies Through the Nigeria Implementation Science Alliance: Getting to Zero in the Prevention of Mother-to-Child Transmission of HIV.

Authors:  Echezona E Ezeanolue; Byron J Powell; Dina Patel; Ayodotun Olutola; Michael Obiefune; Patrick Dakum; Prosper Okonkwo; Bola Gobir; Timothy Akinmurele; Anthea Nwandu; Kwasi Torpey; Bolanle Oyeledum; Muyiwa Aina; Andy Eyo; Obinna Oleribe; Ikoedem Ibanga; John Oko; Chukwuma Anyaike; John Idoko; Muktar H Aliyu; Rachel Sturke; Heather Watts; George Siberry
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

8.  Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.

Authors:  Muktar H Aliyu; Usman J Wudil; Donna J Ingles; Bryan E Shepherd; Wu Gong; Baba M Musa; Hamza Muhammad; Mahmoud U Sani; Aliyu Abdu; Aisha M Nalado; Akinfenwa Atanda; Aima A Ahonkhai; Talat A Ikizler; Cheryl A Winkler; Jeffrey B Kopp; Paul L Kimmel; C William Wester
Journal:  Trials       Date:  2019-06-10       Impact factor: 2.279

Review 9.  The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review.

Authors:  Emily P Hyle; Bongani M Mayosi; Keren Middelkoop; Mosepele Mosepele; Emily B Martey; Rochelle P Walensky; Linda-Gail Bekker; Virginia A Triant
Journal:  BMC Public Health       Date:  2017-12-15       Impact factor: 3.295

View more
  3 in total

1.  Building Physician-Scientist Skills in R Programming:A Short Workshop Report.

Authors:  Muktar H Aliyu; Mahmoud U Sani; Donna J Ingles; Fatima I Tsiga-Ahmed; Baba M Musa; M Shannon Byers; Deepa Dongarwar; Hamisu M Salihu; C William Wester
Journal:  Int J Transl Med Res Public Health       Date:  2022-05-27

2.  Building Research Capacity in HIV and Noncommunicable Diseases in Africa: A Mentorship and Leadership Workshop Report.

Authors:  Muktar H Aliyu; Mahmoud U Sani; Donna J Ingles; Fatimah I Tsiga-Ahmed; Baba M Musa; Aimalohi A Ahonkhai; Hamisu M Salihu; Carolyn M Audet; C William Wester
Journal:  J Contin Educ Health Prof       Date:  2022-01-01       Impact factor: 2.190

3.  Building a national framework for multicentre research and clinical trials: experience from the Nigeria Implementation Science Alliance.

Authors:  John Olajide Olawepo; Echezona Edozie Ezeanolue; Adanma Ekenna; Olabanjo O Ogunsola; Ijeoma Uchenna Itanyi; Elima Jedy-Agba; Emmanuel Egbo; Chukwudi Onwuchekwa; Alexandra Ezeonu; Abiola Ajibola; Babayemi O Olakunde; Omololuoye Majekodunmi; Amaka G Ogidi; JohnBosco Chukwuorji; Nwamaka Lasebikan; Patrick Dakum; Prosper Okonkwo; Bolanle Oyeledun; John Oko; Hadiza Khamofu; Akudo Ikpeazu; Uchechukwu Emmanuel Nwokwu; Gambo Aliyu; Oladapo Shittu; Anne F Rositch; Byron J Powell; Donaldson F Conserve; Gregory A Aarons; Ayodotun Olutola
Journal:  BMJ Glob Health       Date:  2022-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.